Neuroscience
Goetz CG. Scales to evaluate psychosis in Parkinson's disease. Parkinsonism and Related Disorders. 2009 Dec; 15 Suppl 3, 38-341
Hallucinations and psychotic behaviors are a frequent non-motor aspect of Parkinson's disease and its treatment. These behaviors usually do not occur in the presence of the physician and are therefore difficult to rate. Further, because of their bizarre nature, hallucinations are frequently underreported by patients, and caregivers are often unaware of them until they become problematic. A number of scales have been developed for rating these behaviors, most of them borrowed or adapted from assessment tools used in other psychotic disorders like schizophrenia. In the latter disorders, however, hallucinations and psychosis are phenomenologically different than the typical hallucinations of Parkinson's disease. The Movement Disorder Society Task Force on Parkinson's Disease Rating Scales has completed a systematic critique of scales used in clinical trials focusing on hallucinations and psychosis. In this critique, the following scales met the criteria to be classified as Recommended: Neuropsychiatric Inventory, Brief Psychiatric Rating Scale, Positive and Negative Syndrome Scale, and Schedule for Assessment of Positive Symptoms. However, the Task Force felt that each of these scales has significant weaknesses and is insufficient to be considered a definitive rating tool. The Task Force officially recommended the development of a new scale to assess hallucinations and psychosis in Parkinson's disease. This effort is now ongoing with official endorsement by the Movement Disorder Society.
PMID: 20083004 [PubMed - indexed for MEDLINE]
- Neuropsychology Abstract Of The Day: Alzheimer's Disease
Relationships Between Behavioral Syndromes and Cognitive Domains in Alzheimer Disease: The Impact of Mood and Psychosis American Journal of Geriatric Psychiatry. 2011 Nov 1; Koppel J, Goldberg TE, Gordon ML, Huey E, Davies P, Keehlisen L, Huet S, Christen...
- Acadia's Pimavanserin And Parkinson Disease Psychosis
FierceBiotech reported today about a failed Phase III trial of Acadia's Pimavanserin in a study of Parkinson's Disease Psychosis (sometimes abbreviated as "PDP"): ACADIA Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in...
- Rasagiline And Parkinson's Disease
From the FDA on the 17th of May: FDA Approves New Treatment for Parkinson's Disease The Food and Drug Administration today approved Azilect (rasagiline), a new molecular entity, for the treatment of Parkinson's disease. The drug is a monoamine...
- In The Weeklies
This week's issue of the New England Journal of Medicine (09 December 2004) includes two research papers and one editorial comment on topics concerning Parkinson disease: Levodopa and the Progression of Parkinson's Disease by The Parkinson...
- Awareness Month: Parkinson’s Disease
April is National Parkinson's Awareness Month. Parkinson’s disease, a degenerative disorder of the central nervous system, has no known cause in most cases. Medically, Parkinson’s has been traced to the death of dopamine-generating cells in the...
Neuroscience
Neuropsychology Abstract of the Day: Scales to Measure Psychosis in Parkinson's Disease
Goetz CG. Scales to evaluate psychosis in Parkinson's disease. Parkinsonism and Related Disorders. 2009 Dec; 15 Suppl 3, 38-341
Hallucinations and psychotic behaviors are a frequent non-motor aspect of Parkinson's disease and its treatment. These behaviors usually do not occur in the presence of the physician and are therefore difficult to rate. Further, because of their bizarre nature, hallucinations are frequently underreported by patients, and caregivers are often unaware of them until they become problematic. A number of scales have been developed for rating these behaviors, most of them borrowed or adapted from assessment tools used in other psychotic disorders like schizophrenia. In the latter disorders, however, hallucinations and psychosis are phenomenologically different than the typical hallucinations of Parkinson's disease. The Movement Disorder Society Task Force on Parkinson's Disease Rating Scales has completed a systematic critique of scales used in clinical trials focusing on hallucinations and psychosis. In this critique, the following scales met the criteria to be classified as Recommended: Neuropsychiatric Inventory, Brief Psychiatric Rating Scale, Positive and Negative Syndrome Scale, and Schedule for Assessment of Positive Symptoms. However, the Task Force felt that each of these scales has significant weaknesses and is insufficient to be considered a definitive rating tool. The Task Force officially recommended the development of a new scale to assess hallucinations and psychosis in Parkinson's disease. This effort is now ongoing with official endorsement by the Movement Disorder Society.
PMID: 20083004 [PubMed - indexed for MEDLINE]
- Neuropsychology Abstract Of The Day: Alzheimer's Disease
Relationships Between Behavioral Syndromes and Cognitive Domains in Alzheimer Disease: The Impact of Mood and Psychosis American Journal of Geriatric Psychiatry. 2011 Nov 1; Koppel J, Goldberg TE, Gordon ML, Huey E, Davies P, Keehlisen L, Huet S, Christen...
- Acadia's Pimavanserin And Parkinson Disease Psychosis
FierceBiotech reported today about a failed Phase III trial of Acadia's Pimavanserin in a study of Parkinson's Disease Psychosis (sometimes abbreviated as "PDP"): ACADIA Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in...
- Rasagiline And Parkinson's Disease
From the FDA on the 17th of May: FDA Approves New Treatment for Parkinson's Disease The Food and Drug Administration today approved Azilect (rasagiline), a new molecular entity, for the treatment of Parkinson's disease. The drug is a monoamine...
- In The Weeklies
This week's issue of the New England Journal of Medicine (09 December 2004) includes two research papers and one editorial comment on topics concerning Parkinson disease: Levodopa and the Progression of Parkinson's Disease by The Parkinson...
- Awareness Month: Parkinson’s Disease
April is National Parkinson's Awareness Month. Parkinson’s disease, a degenerative disorder of the central nervous system, has no known cause in most cases. Medically, Parkinson’s has been traced to the death of dopamine-generating cells in the...